MorphoSys (ETR:MOR) Given a €13.00 Price Target at Deutsche Bank Aktiengesellschaft

MorphoSys (ETR:MORGet Rating) has been given a €13.00 ($13.27) price target by analysts at Deutsche Bank Aktiengesellschaft in a research report issued on Friday, Borsen Zeitung reports. Deutsche Bank Aktiengesellschaft’s price target suggests a potential downside of 12.19% from the company’s previous close.

Other analysts have also issued reports about the stock. Berenberg Bank set a €65.00 ($66.33) price target on shares of MorphoSys in a research report on Thursday, August 4th. The Goldman Sachs Group set a €24.00 ($24.49) target price on MorphoSys in a report on Thursday, August 4th. Finally, JPMorgan Chase & Co. set a €18.00 ($18.37) price target on MorphoSys in a report on Monday.

MorphoSys Price Performance

MorphoSys stock opened at €14.81 ($15.11) on Friday. The firm has a market capitalization of $505.64 million and a PE ratio of -0.84. MorphoSys has a 52 week low of €13.90 ($14.18) and a 52 week high of €38.11 ($38.89). The firm’s 50-day simple moving average is €19.36 and its 200 day simple moving average is €19.78. The company has a quick ratio of 3.49, a current ratio of 3.76 and a debt-to-equity ratio of 231.51.

About MorphoSys

(Get Rating)

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

See Also

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.